from today's S-3.....
Our lead product, Iloperidone, is currently in Phase III clinical testing
for schizophrenia through a strategic alliance with Novartis Pharma AG. Novartis
has tradenamed the product Zomaril(TM), and the Phase III program, which will
enroll 3,300 patients in 24 countries, has been named the ZEUS(TM) program, for
Zomaril Efficacy/Utility and Safety. Iloperidone is being developed for the
treatment of schizophrenia and related psychotic disorders - a market expected
to exceed $4 billion within two years. Also in the central nervous system arena,
we are developing a unique cell based therapeutic, Spheramine(TM), for the
treatment of Parkinson's disease. Our cancer therapeutics in clinical testing
include three immunotherapeutics --CeaVac(TM), TriAb(TM), and TriGem -- that are
designed to stimulate a patient's immune system against cancer cells. CeaVac(TM)
is currently in multicenter double-blind prospectively controlled Phase II
clinical testing for colorectal cancer. TriAb(TM) is currently in multicenter
double-blind prospectively controlled Phase II clinical testing for breast
cancer. TriGem(TM) has completed Phase I testing in melanoma and we are pursuing
later stage clinical trials through co-operative groups. Another product we have
in development, Pivanex(TM), is a small molecule drug that acts as a cell
differentiating agent. Pivanex is currently in Phase II clinical testing for
non-small cell lung cancer. Additionally, we are developing gene therapy
products for treating various cancers and, with the help of SBIR grants, an
implantable drug delivery system with applications in the treatment of central
nervous system disorders. |
